18F-FAZA PET imaging response tracks the reoxygenation of tumors in mice upon treatment with the mitochondrial complex I inhibitor bay 87-2243

Clinical Cancer Research

Volumn 21, Issue 2, 2015, Pages 335-346

  Chang, Edwin ^a   Liu, Hongguang ^a   Unterschemmann, Kerstin ^b   Ellinghaus, Peter ^b   Liu, Shuanglong ^a   Gekeler, Volker ^c   Cheng, Zhen ^a   Berndorff, Dietmar ^c   Gambhir, Sanjiv S ^a  

^a STANFORD UNIVERSITY   (United States)

^b BAYER AG   (Germany)

^c BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 4 [4 [[5 METHYL 3 [3 [4 (TRIFLUOROMETHOXY)PHENYL] 1,2,4 OXADIAZOL 5 YL] 1H PYRAZOL 1 YL]METHYL]PYRIDIN 2 YL]PIPERAZINE; 3' FLUOROTHYMIDINE F 18; ANGIOPOIETIN; ANGIOPOIETIN LIKE 4 PROTEIN; CARBONATE DEHYDRATASE IX; FAZA F 18; FLUORODEOXYGLUCOSE F 18; FPP(RGD)2 F 18; GLUCOSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE 3; OXIDOREDUCTASE INHIBITOR; RADIOPHARMACEUTICAL AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RNA; UNCLASSIFIED DRUG; 1-CYCLOPROPYL-4-(4-((5-METHYL-3-(3-(4-(TRIFLUOROMETHOXY)PHENYL)-1,2,4-OXADIAZOL-5-YL)-1H-PYRAZOL-1-YL)METHYL)PYRIDIN-2-YL)PIPERAZINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; ANTINEOPLASTIC AGENT; FLUOROAZOMYCIN ARABINOSIDE; NITROIMIDAZOLE DERIVATIVE; OXADIAZOLE DERIVATIVE; PYRAZOLE DERIVATIVE;

786 0 CELL LINE; ANGPTL4 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL PARAMETERS; CA IX GENE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG UPTAKE; EGLN 3 GENE; FEASIBILITY STUDY; FEMALE; GENE EXPRESSION REGULATION; GLUCOSE METABOLISM; H460 CELL LINE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LUNG CANCER CELL LINE; LUNG CARCINOMA; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; PC3 CELL LINE; PHARMACODYNAMICS; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN ANALYSIS; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RENAL CANCER CELL LINE; RNA ANALYSIS; RNA ISOLATION; TUMOR REOXYGENATION; TUMOR VOLUME; TUMOR XENOGRAFT; VESSEL DENSITY; ANIMAL; CELL HYPOXIA; DRUG EFFECTS; DRUG SCREENING; MALE; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; SCINTISCANNING; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL LINE, TUMOR; DIDEOXYNUCLEOSIDES; FEMALE; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE, NUDE; NITROIMIDAZOLES; OXADIAZOLES; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; PYRAZOLES; RADIOPHARMACEUTICALS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921028294     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0217     Document Type: Article

References (39)

1. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002;2:683-93.
2. Tseng JR, Stuart D, Aardalen K, Kaplan A, Aziz N, Hughes NP, et al. Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor. Neoplasia 2011;13:266-75.
3. Tseng JR, Dandekar M, Subbarayan M, Cheng Z, Park JM, Louie S, et al. Reproducibility of 30-deoxy-30-18F-fluorothymidine microPET studies in tumor xenografts in mice. J Nucl Med 2005;46:1851-7.
4. Jiang L, Greenwood TR, Artemov D, Raman V, Winnard PT Jr, Heeren RM, et al. Localized hypoxia results in spatially heterogeneous metabolic signatures in breast tumor models. Neoplasia 2012;14:732-41.
5. Evans SM, Hahn SM, Magarelli DP, Koch CJ. Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am J Clin Oncol 2001;24:467-72.
6. Kaanders JH, Wijffels KI, Marres HA, Ljungkvist AS, Pop LA, van den Hoogen FJ, et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002;62: 7066-74.
7. Finger EC, Giaccia AJ. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev 2010;29:285-93.
8. Chan DA, Giaccia AJ. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 2007;26:333-9.
9. Ellinghaus P, Heisler I, Unterschemmann K, Haerter M, Beck H, Greschat S, et al. BAY 87-2243, a highly potent and selective inhibitor of hypoxiainduced gene activation has antitumor activities and regulates HIF-1a protein expression by inhibition of mitochondrial complex I. Cancer Med 2013;2:611-24.
10. Helbig L, Koi L, Bruchner K, Gurtner K, Hess-Stumpp H, Unterschemmann K, et al. Hypoxia-inducible factor pathway inhibition resolves tumor hypoxia and improves local tumor control after single-dose irradiation. Int J Radiat Oncol Biol Phys 2014;88:159-66.
11. Semenza GL. Life with Oxygen. Science 2007;318:62-4.
12. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
13. Kizaka-Kondoh S, Konse-Nagasawa H. Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia. Cancer Sci 2009;100:1366-73.
14. Chin FT, Shen B, Liu S, Berganos RA, Chang E, Mittra E, et al. First experience with clinical-grade ([(1)(8)F]FPP(RGD(2)): an automated multi-step radiosynthesis for clinical PET studies. Mol Imaging Biol 2012;14:88-95.
15. Dandekar M, Tseng JR, Gambhir SS. Reproducibility of 18F-FDGmicroPET studies in mouse tumor xenografts. J Nucl Med 2007;48:602-7.
16. Souvatzoglou M, Grosu AL, Roper B, Krause BJ, Beck R, Reischl G, et al. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study.Eur J Nucl Med Mol Imaging 2007;34:1566-75.
17. Reischl G, Ehrlichmann W, Bieg C, Solbach C, Kumar P, Wiebe LI, et al. Preparation of the hypoxia imaging PET tracer [18F]FAZA: reaction parameters and automation. Appl Radiat Isot 2005;62:897-901.
18. Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 2005;46:106-13.
19. Picchio M, Beck R, Haubner R, Seidl S, Machulla HJ, Johnson TD, et al. Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18F-FAZA and 125I-Gluco-RGD autoradiography. J Nucl Med 2008;49: 597-605.
20. Knoess C, Siegel S, Smith A, Newport D, Richerzhagen N, Winkeler A, et al. Performance evaluation of the microPET R4 PET scanner for rodents. Eur J Nucl Med Mol Imaging 2003;30:737-47.
21. Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging 1994;13: 601-9.
22. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2003;2:131-7.
23. Pimonidazoleprotocol:. http://search.cosmobio.co.jp/cosmo-search-p/search-gate2/docs/NPI-/HP2100.20080201.pdf.
24. Chang E, Liu S, Gowrishankar G, Yaghoubi S, Wedgeworth JP, Chin F, et al. Reproducibility study of [(18)F]FPP(RGD)2 uptake in murine models of human tumor xenografts. Eur J Nucl Med Mol Imaging 2011;38:722-30.
25. Hendriksen EM, Span PN, Schuuring J, Peters JP, Sweep FC, van der Kogel AJ, et al. Angiogenesis, hypoxia and VEGF expression during tumour growth in a human xenograft tumour model. Microvasc Res 2009;77: 96-103.
26. Young RJ, Moller A. Immunohistochemical detection of tumour hypoxia. Methods Mol Biol 2010;611:151-9.
27. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
28. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008;8:180-92.
29. Masson N, Ratcliffe PJ. Hypoxia signaling pathways in cancermetabolism: the importance of co-selecting interconnected physiological pathways. Cancer Metab 2014;2:3.
30. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009;325:1555-9.
31. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008;49 Suppl 2:129S-48S.
32. Chapman JD. Hypoxic sensitizers-implications for radiation therapy. N Engl J Med 1979;301:1429-32.
33. Beck R, Roper B, Carlsen JM, Huisman MC, Lebschi JA, Andratschke N, et al. Pretreatment 18F-FAZA PET predicts success of hypoxiadirected radiochemotherapy using tirapazamine. J Nucl Med 2007; 48:973-80.
34. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nuclear Med 1995;22:265-80.
35. Miwa GT, West SB, Walsh JS, Wolf FJ, Lu AY. Drug residue formation from ronidazole, a 5-nitroimidazole. III. Studies on the mechanism of protein alkylation in vitro. Chem Biol Interact 1982;41:297-312.
36. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
37. Biswas S, Troy H, Leek R, Chung YL, Li JL, Raval RR, et al. Effects of HIF- 1alpha and HIF2alpha on growth and metabolism of clear-cell renal cell carcinoma 786-0 xenografts. J Oncol 2010;2010: 757908.
38. Hervouet E, Cizkova A, Demont J, Vojtiskova A, Pecina P, Franssen-van Hal NL, et al. HIF and reactive oxygen species regulate oxidative phosphorylation in cancer. Carcinogenesis 2008;29:1528-37.
39. Jiang Y, Zhang W, Kondo K, Klco JM, St Martin TB, Dufault MR, et al. Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. Mol Cancer Res 2003;1:453-62.